# ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves

Study · id `cardio:ct-nct05172973` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05172973](<https://clinicaltrials.gov/study/NCT05172973>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05172973

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT05172973. Non-randomized; no masking; primary purpose treatment. Start 2023-11-22 (actual); primary completion 2029-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT05172973, source copy `cardio:ctgov-nct05172973-2026-10-07`, retrieved 2026-10-26)
- Started: 2023-11-22 (actual) (ClinicalTrials.gov record NCT05172973, source copy `cardio:ctgov-nct05172973-2026-10-07`, retrieved 2026-10-26)
- Primary completion: 2029-03 (anticipated) (ClinicalTrials.gov record NCT05172973, source copy `cardio:ctgov-nct05172973-2026-10-07`, retrieved 2026-10-26)
- Completion: 2039-12 (anticipated) (ClinicalTrials.gov record NCT05172973, source copy `cardio:ctgov-nct05172973-2026-10-07`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT05172973, source copy `cardio:ctgov-nct05172973-2026-10-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05172973-2026-10-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves
- Condition: Aortic Valve Insufficiency
- Condition: Aortic Valve Stenosis
- Intervention (Device): SAPIEN X4/X4S THV
- Lead sponsor: Edwards Lifesciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic regurgitation (`cardio:aortic-regurgitation`)
- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Edwards Lifesciences (`cardio:edwards-lifesciences`)

## Provenance

Content hash: 6680d5bc6b9d30e1868613550fba89d1f9a6b0615c39d63d18868503d2db4c48
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
